Malin FlodstrÃ¶m Tullberg

List of Publications by Year
in descending order

59 papers	1,740 citations	236612 25 h-index	301761 39 g-index
60 all docs	60 docs citations	60 times ranked	2322 citing authors

#	Article	IF	Citations
1	Coxsackie B virus. Trends in Microbiology, 2022, 30, 606-607.	3.5	4
2	The Karolinska <scp>KI</scp>/K <scp>COVID</scp>â€•19 immune atlas: An open resource for immunological research and educational purposes. Scandinavian Journal of Immunology, 2022, 96, .	1.3	4
3	Inhibition of Type III Interferon Expression in Intestinal Epithelial Cellsâ€"A Strategy Used by Coxsackie B Virus to Evade the Hostâ€™s Innate Immune Response at the Primary Site of Infection?. Microorganisms, 2021, 9, 105.	1.6	8
4	Coxsackievirus B Vaccines Prevent Infection-Accelerated Diabetes in NOD Mice and Have No Disease-Inducing Effect. Diabetes, 2021, 70, 2871-2878.	0.3	19
5	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	52
6	Defining the proteolytic landscape during enterovirus infection. PLoS Pathogens, 2020, 16, e1008927.	2.1	36
7	Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine. Microorganisms, 2020, 8, 1287.	1.6	8
8	Corona Pandemic: Assisted Isolation and Care to Protect Vulnerable Populations May Allow Us to Shorten the Universal Lock-Down and Gradually Re-open Society. Frontiers in Public Health, 2020, 8, 562901.	1.3	2
9	A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Science Advances, 2020, 6, eaaz2433.	4.7	55
10	Antibody Responses against Enterovirus Proteases are Potential Markers for an Acute Infection. Viruses, 2020, 12, 78.	1.5	7
11	Human Enterovirus Group B Viruses Rely on Vimentin Dynamics for Efficient Processing of Viral Nonstructural Proteins. Journal of Virology, 2020, 94, .	1.5	22
12	Mouse Models of Virus-Induced Type 1 Diabetes. Methods in Molecular Biology, 2020, 2128, 93-105.	0.4	3
13	Defining the proteolytic landscape during enterovirus infection. , 2020, 16, e1008927.		0
14	Defining the proteolytic landscape during enterovirus infection. , 2020, 16, e1008927.		0
15	Defining the proteolytic landscape during enterovirus infection. , 2020, 16, e1008927.		0
16	Defining the proteolytic landscape during enterovirus infection. , 2020, 16, e1008927.		0
17	Genetic and Environmental Interaction in Type 1 Diabetes: a Relationship Between Genetic Risk Alleles and Molecular Traits of Enterovirus Infection?. Current Diabetes Reports, 2019, 19, 82.	1.7	33
18	Short-term CFTR inhibition reduces islet area in C57BL/6 mice. Scientific Reports, 2019, 9, 11244.	1.6	4

#	Article	IF	Citations
19	Coxsackievirus B Persistence Modifies the Proteome and the Secretome of Pancreatic Ductal Cells. IScience, 2019, 19, 340-357.	1.9	20
20	Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine. Antiviral Research, 2019, 171, 104595.	1.9	15
21	A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine. Vaccine, 2019, 37, 5962-5971.	1.7	19
22	Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]. Diabetologia, 2019, 62, 1100-1103.	2.9	4
23	Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia, 2019, 62, 744-753.	2.9	65
24	Defective exocytosis and processing of insulin in a cystic fibrosis mouse model. Journal of Endocrinology, 2019, 241, 45-57.	1.2	15
25	New Coxsackievirus 2Apro and 3Cpro protease antibodies for virus detection and discovery of pathogenic mechanisms. Journal of Virological Methods, 2018, 255, 29-37.	1.0	13
26	A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses. Scientific Reports, 2018, 8, 33.	1.6	18
27	A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia, 2018, 61, 476-481.	2.9	58
28	Severely Impaired Control of Bacterial Infections in a Patient With Cystic Fibrosis Defective in Mucosal-Associated Invariant T Cells. Chest, 2018, 153, e93-e96.	0.4	26
29	Vitamin D treatment modulates immune activation in cystic fibrosis. Clinical and Experimental Immunology, 2017, 189, 359-371.	1.1	51
30	Composition and functionality of the intrahepatic innate lymphoid cellâ€compartment in human nonfibrotic and fibrotic livers. European Journal of Immunology, 2017, 47, 1280-1294.	1.6	61
31	Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine, 2017, 35, 3718-3725.	1.7	27
32	CFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells. Scientific Reports, 2017, 7, 90.	1.6	48
33	Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial. European Journal of Clinical Nutrition, 2017, 71, 203-205.	1.3	40
34	A Link Between a Common Mutation in CFTR and Impaired Innate and Adaptive Viral Defense. Journal of Infectious Diseases, 2017, 216, 1308-1317.	1.9	9
35	Cystic fibrosis bronchial epithelial cells have impaired ability to activate vitamin D. Acta Paediatrica, International Journal of Paediatrics, 2016, 105, 851-853.	0.7	7
36	An IFIH1 gene polymorphism associated with risk for autoimmunity regulates canonical antiviral defence pathways in Coxsackievirus infected human pancreatic islets. Scientific Reports, 2016, 6, 39378.	1.6	52

#	Article	IF	Citations
37	Enterovirus Exposure Uniquely Discriminates Type 1 Diabetes Patients with a Homozygous from a Heterozygous Melanoma Differentiation-Associated Protein 5/Interferon Induced with Helicase C Domain 1 A946T Genotype. Viral Immunology, 2016, 29, 389-397.	0.6	9
38	Enteroviral proteases: structure, host interactions and pathogenicity. Reviews in Medical Virology, 2016, 26, 251-267.	3.9	72
39	Depletion of ILâ€2 receptor Î²â€positive cells protects from diabetes in nonâ€obese diabetic mice. Immunology and Cell Biology, 2016, 94, 177-184.	1.0	6
40	Coxsackievirus counters the host innate immune response by blocking type III interferon expression. Journal of General Virology, 2016, 97, 1368-1380.	1.3	24
41	A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. Diabetologia, 2015, 58, 346-354.	2.9	41
42	Application of bioinformatics in probe design enables detection of enteroviruses on different taxonomic levels by advanced in situ hybridization technology. Journal of Clinical Virology, 2015, 69, 165-171.	1.6	16
43	Novel Role for Matricellular Proteins in the Regulation of Islet Î² Cell Survival. Journal of Biological Chemistry, 2014, 289, 30614-30624.	1.6	21
44	Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas. Diabetologia, 2014, 57, 392-401.	2.9	35
45	Detection of enterovirus in the islet cells of patients with type 1 diabetes: what do we learn from immunohistochemistry? Reply to Hansson SF, Korsgren S, PontÃ©n F et al [letter]. Diabetologia, 2014, 57, 647-649.	2.9	12
46	Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection. Clinical and Experimental Immunology, 2014, 177, 687-695.	1.1	15
47	CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells. BMC Medicine, 2014, 12, 87.	2.3	106
48	Previous maternal infection protects offspring from enterovirus infection and prevents experimental diabetes development in mice. Diabetologia, 2013, 56, 867-874.	2.9	26
49	Induction of an Antiviral State and Attenuated Coxsackievirus Replication in Type III Interferon-Treated Primary Human Pancreatic Islets. Journal of Virology, 2013, 87, 7646-7654.	1.5	36
50	Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes. Clinical and Experimental Immunology, 2012, 168, 30-38.	1.1	34
51	Melanoma differentiation-associated protein-5 (MDA-5) limits early viral replication but is not essential for the induction of type 1 interferons after Coxsackievirus infection. Virology, 2010, 401, 42-48.	1.1	45
52	The target cell response to cytokines governs the autoreactive T cell repertoire in the pancreas of NOD mice. Diabetologia, 2009, 52, 299-305.	2.9	16
53	Natural killer cells in human autoimmunity. Current Opinion in Immunology, 2009, 21, 634-640.	2.4	94
54	The target tissue in autoimmunity â€" an influential niche. European Journal of Immunology, 2007, 37, 589-597.	1.6	24

#	Article	IF	Citations
55	IFN-Î³ production dominates the early human natural killer cell response to Coxsackievirus infection. Cellular Microbiology, 2007, 10, 071027034427001-???.	1.1	26
56	Interferons induce an antiviral state in human pancreatic islet cells. Virology, 2007, 367, 92-101.	1.1	85
57	RNase L and Double-Stranded RNA-Dependent Protein Kinase Exert Complementary Roles in Islet Cell Defense during Coxsackievirus Infection. Journal of Immunology, 2005, 174, 1171-1177.	0.4	91
58	Viral infections: their elusive role in regulating susceptibility to autoimmune disease. Microbes and Infection, 2003, 5, 911-921.	1.0	24
59	Target Cell Expression of Suppressor of Cytokine Signaling-1 Prevents Diabetes in the NOD Mouse. Diabetes, 2003, 52, 2696-2700.	0.3	77